SCHEMBL799740

SCHEMBL799740

CCNC(=O)CBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14369161 0.90 MCL1 (0.41)
SCHEMBL25439325 0.79 MCL1 (0.38)
SCHEMBL4997115 0.78
SCHEMBL12073662 0.78
SCHEMBL5909428 0.78 MCL1 (0.55)
SCHEMBL10013645 0.78 MEN1 (0.39)
SCHEMBL95875 0.75
SCHEMBL5909462 0.75 FAAH (0.64)
SCHEMBL10866810 0.75 HDAC3 (0.41)
SCHEMBL3310816 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577228-B2 Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds UCB Biopharma SRL (BE) 2026-03-17 US disclosed
EP-4081296-B1 DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS UCB Biopharma SRL (BE) 2026-02-11 EP disclosed
US-20250288573-A1 DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2025-09-18 US disclosed
US-12233054-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2025-02-25 US disclosed
US-20240165095-A1 DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2024-05-23 US disclosed
EP-3782995-B1 SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES SHANGHAI INST MATERIA MEDICA CAS (CN) 2023-11-22 EP disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 US disclosed
US-20230357846-A1 POLYMER COATINGS ILLUMINA, INC. 2023-11-09 US disclosed
US-20230303517-A1 DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) 2023-09-28 US disclosed
US-20230270876-A1 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES NOVARTIS AG (CH) 2023-08-31 US disclosed
US-20050182088-A1 Modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-08-18 US disclosed
EP-1472248-A1 MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-11-03 EP disclosed
WO-2003062235-A1 MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed
EP-1240145-A2 SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THE USE THEREOF Bayer Aktiengesellschaft (DE) 2002-09-18 EP disclosed
WO-2001025210-A2 SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THE USE THEREOF AS ADENOSINE RECEPTOR LIGANDS BAYER AKTIENGESELLSCHAFT (DE) 2001-04-12 WO disclosed
US-6124303-A MODULATING APOPTOSIS AND ELIMINATING AND INHIBITING GROWTH OF NEOPLASIAS SUCH AS PRECANCEROUS LESIONS CELL PATHWAYS, INC. (US) 2000-09-26 US disclosed
US-5079357-A Bactericides DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-01-07 US disclosed
US-4962202-A PENICILLIN INTERMEDIATES DAIICHI SEIYAKU CO., LTD. (JP) 1990-10-09 US disclosed
US-4644012-A WITH 3-PHENYL-4H-1-BENZOPYRAN-4-ONE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-02-17 US disclosed
EP-0146921-A2 Method for treating osteoporosis Takeda Chemical Industries, Ltd. (JP) 1985-07-03 EP disclosed